The Italian Competition Authority on Wednesday announced an investigation into Biogen (BIIB) over alleged abuse of market ...

Switzerland’s Sandoz sees Canada and Brazil markets as testing grounds before semaglutide goes off patent in Europe and the U.S. in the 2030s.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Q1 2026 trading update and why it matters for Sandoz shares Sandoz Group (SWX:SDZ) has just reported its Q1 2026 trading update, with 3% net sales growth at constant currencies and an 18% rise in ...

(Reuters) -Sandoz shares dipped on their market debut on Wednesday after the generic and biosimilar drugmaker was valued at a lower-than-expected 10.3 billion Swiss francs ($11.2 billion) in its ...

Sandoz confirmed that the European Commission has granted marketing authorization for Bysumlog (insulin lispro) and Dazparda ...

To achieve its 10-year goals, Sandoz said it has established a sustainability blueprint that reduces emissions.

Spin-off from Novartis successfully completed with first trading day on SIX Swiss Exchange; Sandoz shares included in key market indices Standalone Sandoz committed to extend leadership in stable and ...

LONDON (Reuters) - Novartis' soon-to-be spun off generics division Sandoz is betting on biosimilars, copies of high-priced drugs used to treat illnesses such as rheumatoid arthritis and cancer, to ...

Ever wondered if Sandoz Group stock could be a hidden value play, or if you're just jumping in after the most exciting moves? Let's find out what might actually be under the hood. After a rocky 2.4% ...

The Swiss drugmaker announced intentions to spin off the Sandoz business in August, offering stakeholders one Sandoz share for every five Novartis shares via a dividend-in-kind distribution. Novartis ...